The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor

References

• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• ChunhachaPChanvorachotePRoles of caveolin-1 on anoikis resistance in non small cell lung cancerInt J Physiol Pathophysiol Pharmacol20124314915523071872
   PubMedGoogle Scholar
• VázquezSCasalJAfonso AfonsoFJEGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)Cancer Manag Res20168112026893581
   PubMed Web of Science ®Google Scholar
• GuoWJLiuSHZhangXLThe coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancerDrug Des Devel Ther In press2017
   Web of Science ®Google Scholar
• HamiltonGRathBDetection of circulating tumor cells in non-small cell lung cancerJ Thorac Dis201681024102827293809
   PubMed Web of Science ®Google Scholar
• ScagliottiGVDe MarinisFRinaldiMItalian Lung Cancer ProjectPhase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancerJ Clin Oncol200220214285429112409326
   PubMed Web of Science ®Google Scholar
• NestleUNiederCWalterKA palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence studyInt J Radiat Oncol Biol Phys20004819510310924977
   PubMed Web of Science ®Google Scholar
• YochumZASocinskiMABurnsTFParadoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistanceJ Thorac Dis2016811E1528E153128066651
   PubMed Web of Science ®Google Scholar
• ValdespinoVValdespinoPMPotential of epigenetic therapies in the management of solid tumorsCancer Manag Res2015724125126346546
   PubMed Web of Science ®Google Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discov20144666267324675041
   PubMed Web of Science ®Google Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol201693427071706
   PubMed Web of Science ®Google Scholar
• WangSSongYYanFLiuDMechanisms of resistance to third-generation EGFR tyrosine kinase inhibitorsFront Med201610438338827770386
   PubMed Web of Science ®Google Scholar
• IragavarapuCMustafaMAkinleyeANovel ALK inhibitors in clinical use and developmentJ Hematol Oncol201581725888090
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res20091593143314919383809
   PubMed Web of Science ®Google Scholar
• SchaeferESBaikCProactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancerCancer Manag Res20168333827069372
   PubMed Web of Science ®Google Scholar
• RikovaKGuoAZengQGlobal survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancerCell200713161190120318083107
   PubMed Web of Science ®Google Scholar
• EttingerDSAkerleyWBorghaeiHNational comprehensive cancer networkNon-small cell lung cancerJ Natl Compr Canc Netw2012101236127123054877
   PubMed Web of Science ®Google Scholar
• JoshiMRizviSMBelaniCPAfatinib for the treatment of metastatic non-small cell lung cancerCancer Manag Res20157758225733926
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• OuSHJännePABartlettCHClinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCAnn Oncol201425241542224478318
   PubMed Web of Science ®Google Scholar
• OuSHAhnJSDe PetrisLAlectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global studyJ Clin Oncol201634766166826598747
   PubMed Web of Science ®Google Scholar
• ZouHYFribouletLKodackDPPF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical modelsCancer Cell2015281708126144315
   PubMed Web of Science ®Google Scholar
• SolomonBJBauerTMFelipESafety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)J Clin Oncol2016349009
   Web of Science ®Google Scholar
• ShawATFribouletLLeshchinerIResensitization to crizotinib by the lorlatinib ALK resistance mutation L1198FN Engl J Med20163741546126698910
   PubMed Web of Science ®Google Scholar
• PagetSThe distribution of secondary growths in cancer of the breast. 1889Cancer Metastasis Rev198982981012673568
   PubMed Web of Science ®Google Scholar
• RolfoCCastigliaMHongDLiquid biopsies in lung cancer: the new ambrosia of researchersBiochim Biophys Acta20141846253954625444714
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAKantarjianHMCortesJEMechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemiaCancer Control200916212213119337198
   PubMed Web of Science ®Google Scholar
• MokTKimDWWuYLFirst-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)J Clin Oncol2014328002
   Web of Science ®Google Scholar
• HeuckmannJMBalke-WantHMalchersFDifferential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variantsClin Cancer Res201218174682469022912387
   PubMed Web of Science ®Google Scholar
• HeuckmannJMHölzelMSosMLALK mutations conferring differential resistance to structurally diverse ALK inhibitorsClin Cancer Res201117237394740121948233
   PubMed Web of Science ®Google Scholar
• ShawATSolomonBKenudsonMMCrizotinib and testing for ALKJ Natl Compr Canc Netw20119121335134122157554
   PubMed Web of Science ®Google Scholar
• KanedaHYoshidaTOkamotoIMolecularly targeted approaches herald a new era of non-small-cell lung cancer treatmentCancer Manag Res201359110123785245
   PubMedGoogle Scholar
• LindemanNICaglePTBeasleyMBMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyJ Thorac Oncol20138782385923552377
   PubMed Web of Science ®Google Scholar
• CamidgeDRKonoSAFlaccoAOptimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatmentClin Cancer Res201016225581559021062932
   PubMed Web of Science ®Google Scholar
• CondeEHernandezSPrietoMMartinezRLopez-RiosFProfile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomasExpert Rev Mol Diagn201616670771327031368
   PubMed Web of Science ®Google Scholar
• JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol201028235736019949011
   PubMed Web of Science ®Google Scholar
• WuJSavoojiJLiuDSecond- and third-generation ALK inhibitors for non-small cell lung cancerJ Hematol Oncol201691926951079
   PubMed Web of Science ®Google Scholar
• ToyokawaGSetoTUpdated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical dataOncol Res Treat201538629129826045026
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung CancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashitaYALK Lung Cancer Study GroupEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• SasakiTOkudaKZhengWThe neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancersCancer Res20107024100381004321030459
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• CroegaertKKolesarJMRole of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancerAm J Health Syst Pharm201572171456146226294238
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• GainorJFDardaeiLYodaSMolecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancerCancer Discov20166101118113327432227
   PubMed Web of Science ®Google Scholar
• PetersSAdjeiAAGridelliCReckMKerrKFelipEESMO Guidelines Working GroupMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii56vii6422997455
   PubMed Web of Science ®Google Scholar
• BolandJMJangJSLiJMET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive casesJ Thorac Oncol20138557458123449277
   PubMed Web of Science ®Google Scholar
• MosséYPWoodAMarisJMInhibition of ALK signaling for cancer therapyClin Cancer Res200915185609561419737948
   PubMed Web of Science ®Google Scholar
• ChiarleRSimmonsWJCaiHStat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetNat Med200511662362915895073
   PubMed Web of Science ®Google Scholar
• TakezawaKOkamotoINishioKJännePANakagawaKRole of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancerClin Cancer Res20111782140214821415216
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci U S A2011108187535754021502504
   PubMed Web of Science ®Google Scholar
• RenSWuCLiXZhaoCHouLZhouCIncidence of inconsistent driver mutations between multiple lung ground-glass nodules in patients with non-small cell lung cancerJ Clin Oncol20143215 Suppl11068
   Web of Science ®Google Scholar
• ChaYJChoBCKimHRLeeHJShimHSA case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinibJ Thorac Oncol2016115e55e5826752677
   PubMed Web of Science ®Google Scholar
• TakegawaNHayashiHIizukaNTransformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinibAnn Oncol2016275953955
   PubMed Web of Science ®Google Scholar
• Ignatius OuSHAzadaMHsiangDJNext-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinibJ Thorac Oncol20149454955324736079
   PubMed Web of Science ®Google Scholar
• YouLShouJDengDCrizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell linesOncotarget2015637402684028226384345
   PubMed Web of Science ®Google Scholar
• GuptaGPMassaguéJCancer metastasis: building a frameworkCell2006127467969517110329
   PubMed Web of Science ®Google Scholar
• AllanALKeeneyMCirculating tumor cell analysis: technical and statistical considerations for application to the clinicJ Oncol2010201042621820049168
   PubMedGoogle Scholar
• TossAMuZFernandezSCristofanilliMCTC enumeration and characterization: moving toward personalized medicineAnn Transl Med201421110825489582
   PubMedGoogle Scholar
• TammingaMGroenHHHiltermannTJInvestigating CTCs in NSCLC-a reaction to the study of Jia-Wei Wan: a preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancerJ Thorac Dis2016861032103627293811
   PubMed Web of Science ®Google Scholar
• MengSTripathyDFrenkelEPCirculating tumor cells in patients with breast cancer dormancyClin Cancer Res200410248152816215623589
   PubMed Web of Science ®Google Scholar
• LeongSMTanKMChuaHWSampling circulating tumor cells for clinical benefits: how frequent?J Hematol Oncol201587526108208
   PubMed Web of Science ®Google Scholar
• ZhangZShiratsuchiHPalanisamyNNagrathSRamnathNExpanded circulating tumor cells from a patient with ALK-positive lung cancer present with EML4-ALK rearrangement along with resistance mutation and enable drug sensitivity testing: a case studyJ Thorac Oncol201712239740227507192
   PubMed Web of Science ®Google Scholar
• AietaMFacchinettiADe FaveriSMonitoring and characterization of circulating tumor cells (CTCs) in a patient with EML4-ALK-positive non-small cell lung cancer (NSCLC)Clin Lung Cancer2016175e173e17727397482
   PubMed Web of Science ®Google Scholar
• YangJJZhangXCSuJLung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationClin Cancer Res20142051383139224443522
   PubMed Web of Science ®Google Scholar
• NormantEPaezGWestKAThe Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC modelsOncogene201130222581258621258415
   PubMed Web of Science ®Google Scholar
• GainorJFShawATEmerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancerJ Clin Oncol201331313987399624101047
   PubMed Web of Science ®Google Scholar
• KuangYRogersAYeapBYNoninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancerClin Cancer Res20091582630263619351754
   PubMed Web of Science ®Google Scholar
• SunWYuanXTianYNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerJ Hematol Oncol201589526227959
   PubMed Web of Science ®Google Scholar
• ShawJAStebbingJCirculating free DNA in the management of breast cancerAnn Transl Med201421325332979
   PubMedGoogle Scholar
• JahrSHentzeHEnglischSDNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cellsCancer Res20016141659166511245480
   PubMed Web of Science ®Google Scholar
• DiehlFSchmidtKChotiMACirculating mutant DNA to assess tumor dynamicsNat Med200814998599018670422
   PubMed Web of Science ®Google Scholar
• NewmanAMBratmanSVToJAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageNat Med201420554855424705333
   PubMed Web of Science ®Google Scholar
• JenkinsSYangJCRamalingamSSPlasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancerJ Thorac Oncol20171271061107028428148
   PubMed Web of Science ®Google Scholar
• ChabonJJSimmonsADLovejoyAFCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsNat Commun201671181527283993
   PubMed Web of Science ®Google Scholar
• EscriuCFieldJKCirculating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancerJ Thorac Dis2016892357235927746975
   PubMed Web of Science ®Google Scholar
• WangYTianPWWangWYNoninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencingOncotarget2016740652086521727564104
   PubMedGoogle Scholar
• CooperMRChimHChanHDurandCCeritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancerAnn Pharmacother201549110711225258420
   PubMed Web of Science ®Google Scholar
• OuSILeeTKYoungLDual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?Lung Cancer201710611011428285684
   PubMed Web of Science ®Google Scholar
• GridelliCPetersSSgambatoACasaluceFAdjeiAACiardielloFALK inhibitors in the treatment of advanced NSCLCCancer Treat Rev201440230030623931927
   PubMed Web of Science ®Google Scholar
• PunnooseEAAtwalSLiuWEvaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinibClin Cancer Res20121882391240122492982
   PubMed Web of Science ®Google Scholar
• GevaSRoismanLCPeledNLiquid biopsy in the practice of neooncologyJ Thorac Dis2016810E1279E128127867607
   PubMed Web of Science ®Google Scholar
• ZhouQYangJJChenZHSerial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialJ Hematol Oncol2016918627619632
   PubMed Web of Science ®Google Scholar
• RodríguezMSilvaJLópez-AlfonsoADifferent exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancerGenes Chromosomes Cancer201453971372424764226
   PubMed Web of Science ®Google Scholar
• TavernaSGiallombardoMGil-BazoIExosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practiceOncotarget2016719287482876026919248
   PubMedGoogle Scholar
• ThéryCZitvogelLAmigorenaSExosomes: composition, biogenesis and functionNat Rev Immunol20022856957912154376
   PubMed Web of Science ®Google Scholar
• MathivananSFahnerCJReidGESimpsonRJExoCarta 2012: database of exosomal proteins, RNA and lipidsNucleic Acids Res201240Database issueD1241D124421989406
   PubMed Web of Science ®Google Scholar
• Demory BecklerMHigginbothamJNFranklinJLProteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRASMol Cell Proteomics201312234335523161513
   PubMed Web of Science ®Google Scholar
• TaylorDDGercel-TaylorCMicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancerGynecol Oncol20081101132118589210
   PubMed Web of Science ®Google Scholar
• KosakaNTakeshitaFYoshiokaYExosomal tumor-suppressive microRNAs as novel cancer therapy: “exocure” is another choice for cancer treatmentAdv Drug Deliv Rev201365337638222841506
   PubMed Web of Science ®Google Scholar
• JaiswalRGongJSambasivamSMicroparticle-associated nucleic acids mediate trait dominance in cancerFASEB J201226142042921965597
   PubMed Web of Science ®Google Scholar
• PigatiLYaddanapudiSCIyengarRSelective release of microRNA species from normal and malignant mammary epithelial cellsPLoS One2010510e1351520976003
   PubMed Web of Science ®Google Scholar
• ChuangJCJonesPAEpigenetics and microRNAsPediatr Res2007615 Pt 224R29R
   PubMed Web of Science ®Google Scholar
• LuJGetzGMiskaEAMicroRNA expression profiles classify human cancersNature2005435704383483815944708
   PubMed Web of Science ®Google Scholar
• AnglicheauDMuthukumarTSuthanthiranMMicroRNAs: small RNAs with big effectsTransplantation201090210511220574417
   PubMed Web of Science ®Google Scholar
• ShyuABWilkinsonMFvan HoofAMessenger RNA regulation: to translate or to degradeEMBO J200827347148118256698
   PubMed Web of Science ®Google Scholar
• CalinGACroceCMMicroRNA signatures in human cancersNat Rev Cancer200661185786617060945
   PubMed Web of Science ®Google Scholar
• GarzonRCalinGACroceCMMicroRNAs in cancerAnnu Rev Med20096016717919630570
   PubMed Web of Science ®Google Scholar
• GalluzziLMorselliEVitaleImiR-181a and miR-630 regulate cisplatin-induced cancer cell deathCancer Res20107051793180320145152
   PubMed Web of Science ®Google Scholar
• DacicSKellyLShuaiYNikiforovaMNmiRNA expression profiling of lung adenocarcinomas: correlation with mutational statusMod Pathol201023121577158220818338
   PubMed Web of Science ®Google Scholar
• WuXXiaoHmiRNAs modulate the drug response of tumor cellsSci China C Life Sci200952979780119802736
   PubMedGoogle Scholar
• YanaiharaNCaplenNBowmanEUnique microRNA molecular profiles in lung cancer diagnosis and prognosisCancer Cell20069318919816530703
   PubMed Web of Science ®Google Scholar
• EnfieldKSStewartGLPikorLAMicroRNA gene dosage alterations and drug response in lung cancerJ Biomed Biotechnol2011201147463221541180
   PubMedGoogle Scholar
• VlassovAVMagdalenoSSetterquistRConradRExosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentialsBiochim Biophys Acta20121820794094822503788
   PubMed Web of Science ®Google Scholar
• NilssonRJKarachaliouNBerenguerJRearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancerOncotarget2016711066107526544515
   PubMed Web of Science ®Google Scholar
• ChenSZhaoJCuiLLiuYUrinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIsClin Transl Oncol201719333234027468867
   PubMed Web of Science ®Google Scholar
• LiYZhangYQiuFQiuZProteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLCElectrophoresis201132151976198321557262
   PubMed Web of Science ®Google Scholar
• ZhangLXiaoHZhouHDevelopment of transcriptomic biomarker signature in human saliva to detect lung cancerCell Mol Life Sci201269193341335022689099
   PubMed Web of Science ®Google Scholar
• WeiFYangJWongDTDetection of exosomal biomarker by electric field-induced release and measurement (EFIRM)Biosens Bioelectron20134411512123402739
   PubMed Web of Science ®Google Scholar
• WeiFLinCCJoonANoninvasive saliva-based EGFR gene mutation detection in patients with lung cancerAm J Respir Crit Care Med2014190101117112625317990
   PubMed Web of Science ®Google Scholar
• PuDLiangHWeiFEvaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: a pilot studyThorac Cancer20167442843627385985
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med200521e1715696205
   PubMed Web of Science ®Google Scholar
• MeloskyBTreatment algorithms for patients with metastatic non-small cell, non-squamous lung cancerFront Oncol2014425625325013
   PubMedGoogle Scholar
• YeTPanYWangRAnalysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years oldJ Thorac Dis20146101396140225364516
   PubMed Web of Science ®Google Scholar
• FaraceFMassardCVimondNA direct comparison of Cell-Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomasBr J Cancer2011105684785321829190
   PubMed Web of Science ®Google Scholar
• PaillerEOulhenMBorgetICirculating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patientsCancer Res20177792222223028461563
   PubMed Web of Science ®Google Scholar
• Zito MarinoFRoccoGMorabitoAA new look at the ALK gene in cancer: copy number gain and amplificationExpert Rev Anticancer Ther201616549350226943457
   PubMed Web of Science ®Google Scholar
• BratmanSVNewmanAMAlizadehAADiehnMPotential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-SeqExpert Rev Mol Diagn201515671571925773944
   PubMed Web of Science ®Google Scholar
• WangCWangAWeiFWongDTWTuMElectric field-induced disruption and releasing viable content from extracellular vesiclesMethods Mol Biol2017166036737628828672
   PubMedGoogle Scholar
• ReckMPopatSReinmuthNDe RuysscherDKerrKMPetersSESMO Guidelines Working GroupMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425 Suppl 3iii27iii3925115305
   PubMed Web of Science ®Google Scholar